10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
US biopharma Sage Therapeutics looks all but certain to secure US approval for Zulresso (brexanolone) in postpartum depression after Food and Drug Administration (FDA) advisory committees supported its benefit-risk profile by 17 votes to one. 5 November 2018
The US Food and Drug Administration has approved Lorbrena (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI). 5 November 2018
With 26 potential blockbusters in confirmatory development and 13 projects in clinical development across cell, gene and radioligand therapies, Swiss pharma giant Novartis says it plans to make 60 major regulatory submissions between 2019 and 2021. 5 November 2018
Despite the disappointing history of drug development in pancreatic cancer, the current therapeutic pipeline and clinical development is headed in a promising direction, a new report notes. 5 November 2018
Embark Biotech and Novo Nordisk have joined forces in a new collaboration to develop treatments for obesity and associated metabolic pathologies. 2 November 2018
US drugmaker AbbVie has seen enough promise from its collaboration with Swedish biotech BioArctic (STO: BIOA-B) to exercise its option to license a portfolio of antibodies. 2 November 2018
An abstract published by Actinium Pharmaceuticals in advance of the American Society of Hematology (ASH) meeting in December indicates dramatic results for Iomab-B in from the preliminary safety and feasibility readout from its on-going SIERRA pivotal Phase III trial in R/R AML (relapsed/refractory acute myeloid leukemia), comments Dr Chris Redhead, an analyst at Goetzpartners. 2 November 2018
London-listed rare disease specialist Shire has released its third quarter results, revealing sales of $3.8 billion, in line with analysts’ expectations, and 6% higher than the same period in 2017. 1 November 2018
This morning abstracts for the American Society of Hematology (ASH) meeting became available online, showing data from the Phase III luspatercept studies in myelodysplastic syndromes (MDS) and beta-thalassemia that were not previously disclosed in the top-line press releases by Celgene. 1 November 2018
Fresh from presenting some of the most encouraging quarterly results in recent memory, Sanofi has taken another bet on increasing its future revenues. 1 November 2018
The Australian government has made a new medicine available, from today, for free for an extremely rare and potentially life-threatening disease, saving patients hundreds of thousands of dollars a year. 1 November 2018
The European Commission has approved Venclyxto (venetoclax) in combination with MabThera (rituximab) for chronic lymphocytic leukemia (CLL) patients who have received at least one prior therapy. 1 November 2018
USA-based cancer therapy discoverer Tango Therapeutics has entered into a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer which could earn the venture capital-backed firm $1.75 billion. 31 October 2018
Signalling its intention to grow its biopharma business in the USA, Danish diabetes giant Novo Nordisk (NOV: N) has bought the US and Canadian rights to Macrilen (macimorelin), from Strongbridge Biopharma. 31 October 2018
A UK government report on trends in the life sciences from 2009 to 2017 has found that the sector was broadly characterized by steady growth in terms of business numbers, jobs and turnover. 30 October 2018
In yet another deal with the Swiss pharma giant, US biotech Halozyme Therapeutics has licensed its ENHANZE drug-delivery technology to Roche for exclusive development of a new undisclosed clinical stage therapeutic target, with an option to select two additional targets within four years. 30 October 2018
Evidence of an effective new treatment for Alzheimer’s would create shock waves across healthcare, given the extent of the global need among millions of patients. 30 October 2018
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024